Intranasal esketamine for treatment-resistant depression: real-world effectiveness in electroconvulsive therapy non-responders
The European Journal of Psychiatry March 7, 2026 Rocío Gómez-juanes, Guillermo Mompaler Lázaro, Adoración Castro et al. 1 citation
Intranasal esketamine represents a novel therapeutic option for Treatment-Resistant Depression (TRD). However, its medium-to-long-term risk-benefit profile in real-world clinical practice remains controversial. Limited data is available regarding its effectiveness, particularly in patients who have not responded to electroconvulsive therapy (ECT), which is the focus of this study. We conducted...